Survey of Resistance of Pseudomonas Aeruginosa from UK Patients with Cystic Fibrosis to Six Commonly Prescribed Antimicrobial Agents

Overview

Journal Thorax

Date 2003 Aug 30

PMID 12947141

Citations 49

Authors

T L Pitt

M Sparrow

M Warner

M Stefanidou

Affiliations

Soon will be listed here.

Abstract

Background: Respiratory infection with Pseudomonas aeruginosa is very common in patients with cystic fibrosis (CF) but antimicrobial resistance rates of CF isolates across the UK are largely unknown.

Methods: The susceptibility of 417 CF patient isolates of P aeruginosa from 17 hospitals to six commonly prescribed antibiotics were examined. Isolates were tested by an agar break point dilution method and E-tests according to British Society of Antimicrobial Chemotherapy guidelines. Genotyping of isolates was performed by XbaI DNA macrorestriction and pulsed field gel electrophoresis.

Results: 38% of isolates were susceptible to all of the agents tested; almost half were resistant to gentamicin compared with ceftazidime (39%), piperacillin (32%), ciprofloxacin (30%), tobramycin (10%), and colistin (3%). Approximately 40% were resistant to two or more compounds with ceftazidime in combination with gentamicin, piperacillin or ciprofloxacin being the most common cross resistances. Resistance rates were generally similar to those reported recently from the USA and Germany. A selection of resistant isolates proved to be predominantly genotypically distinct by XbaI DNA macrorestriction but six pairs from three centres had similar genotypes.

Conclusions: The level of resistance to front line antipseudomonal agents, with the exception of colistin, is disturbingly high. The prudent use of antimicrobial drugs and closer monitoring of accumulation of resistant strain populations should be actively considered.

Citing Articles

Development, Characterization, and Antimicrobial Evaluation of Hybrid Nanoparticles (HNPs) Based on Phospholipids, Cholesterol, Colistin, and Chitosan Against Multidrug-Resistant Gram-Negative Bacteria.

Perdomo I, Mora C, Pinillos J, Onate-Garzon J, Salamanca C Pharmaceutics. 2025; 17(2).

PMID: 40006549 PMC: 11859251. DOI: 10.3390/pharmaceutics17020182.

Aspartic acid unveils as antibiofilm agent and tobramycin adjuvant against mucoid and small colony variants of isolates within cystic fibrosis airway mucus.

Monteiro R, Sousa A, Pereira M Biofilm. 2025; 9:100252.

PMID: 39866543 PMC: 11759549. DOI: 10.1016/j.bioflm.2024.100252.

Prevalence of colistin resistance in clinical isolates of : a systematic review and meta-analysis.

Narimisa N, Keshtkar A, Dadgar-Zankbar L, Bostanghadiri N, Far Y, Shahroodian S Front Microbiol. 2024; 15:1477836.

PMID: 39473844 PMC: 11520190. DOI: 10.3389/fmicb.2024.1477836.

Scorpionfish BPI is highly active against multiple drug-resistant isolates from people with cystic fibrosis.

Holzinger J, Toelge M, Werner M, Ederer K, Siegmund H, Peterhoff D Elife. 2023; 12.

PMID: 37461324 PMC: 10353861. DOI: 10.7554/eLife.86369.

The role of nanotechnology-based approaches for clinical infectious diseases and public health.

Chen X, Xu J, Ji B, Fang X, Jin K, Qian J Front Bioeng Biotechnol. 2023; 11:1146252.

PMID: 37077227 PMC: 10106617. DOI: 10.3389/fbioe.2023.1146252.

References

Livermore D . Multiple mechanisms of antimicrobial resistance in Pseudomonas aeruginosa: our worst nightmare?. Clin Infect Dis. 2002; 34(5):634-40. DOI: 10.1086/338782. View

Schulin T . In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother. 2002; 49(2):403-6. DOI: 10.1093/jac/49.2.403. View

Govan J, Doherty C, Glass S . Rational parameters for antibiotic therapy in patients with cystic fibrosis. Infection. 1987; 15(4):300-7. DOI: 10.1007/BF01644142. View

Morlin G, Hedges D, Smith A, Burns J . Accuracy and cost of antibiotic susceptibility testing of mixed morphotypes of Pseudomonas aeruginosa. J Clin Microbiol. 1994; 32(4):1027-30. PMC: 267174. DOI: 10.1128/jcm.32.4.1027-1030.1994. View

Ciofu O, Giwercman B, Pedersen S, Hoiby N . Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center. APMIS. 1994; 102(9):674-80. View

Wolter J, Kotsiou G, McCormack J . Mixed morphotype testing of Pseudomonas aeruginosa cultures from cystic fibrosis patients. J Med Microbiol. 1995; 42(3):220-4. DOI: 10.1099/00222615-42-3-220. View

Chen H, Yuan M, Livermore D . National survey of susceptibility to antimicrobials amongst clinical isolates of Pseudomonas aeruginosa. J Antimicrob Chemother. 1995; 35(4):521-34. DOI: 10.1093/jac/35.4.521. View

Marley E, Mohla C, Campos J . Evaluation of E-Test for determination of antimicrobial MICs for Pseudomonas aeruginosa isolates from cystic fibrosis patients. J Clin Microbiol. 1995; 33(12):3191-3. PMC: 228671. DOI: 10.1128/jcm.33.12.3191-3193.1995. View

Gunn J, Lim K, Krueger J, Kim K, Guo L, Hackett M . PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol. 1998; 27(6):1171-82. DOI: 10.1046/j.1365-2958.1998.00757.x. View

10.

Taccetti G, Campana S, Marianelli L . Multiresistant non-fermentative gram-negative bacteria in cystic fibrosis patients: the results of an Italian multicenter study. Italian Group for Cystic Fibrosis microbiology. Eur J Epidemiol. 1999; 15(1):85-8. DOI: 10.1023/a:1007504524034. View

11.

Wolter J, Bowler S, McCormack J . Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?. Aust N Z J Med. 1999; 29(1):15-21. DOI: 10.1111/j.1445-5994.1999.tb01583.x. View

12.

KING E, Ward M, RANEY D . Two simple media for the demonstration of pyocyanin and fluorescin. J Lab Clin Med. 1954; 44(2):301-7. View

13.

DORING G, Conway S, Heijerman H, Hodson M, Hoiby N, Smyth A . Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus. Eur Respir J. 2000; 16(4):749-67. DOI: 10.1034/j.1399-3003.2000.16d30.x. View

14.

Henwood C, Livermore D, James D, Warner M . Antimicrobial susceptibility of Pseudomonas aeruginosa: results of a UK survey and evaluation of the British Society for Antimicrobial Chemotherapy disc susceptibility test. J Antimicrob Chemother. 2001; 47(6):789-99. DOI: 10.1093/jac/47.6.789. View

15.

MacGowan A, Wise R . Establishing MIC breakpoints and the interpretation of in vitro susceptibility tests. J Antimicrob Chemother. 2001; 48 Suppl 1:17-28. DOI: 10.1093/jac/48.suppl_1.17. View

16.

Jones A, Govan J, Doherty C, Dodd M, Isalska B, Stanbridge T . Spread of a multiresistant strain of Pseudomonas aeruginosa in an adult cystic fibrosis clinic. Lancet. 2001; 358(9281):557-8. DOI: 10.1016/s0140-6736(01)05714-2. View

17.

McCallum S, Corkill J, Gallagher M, Ledson M, Hart C, Walshaw M . Superinfection with a transmissible strain of Pseudomonas aeruginosa in adults with cystic fibrosis chronically colonised by P aeruginosa. Lancet. 2001; 358(9281):558-60. DOI: 10.1016/s0140-6736(01)05715-4. View

18.

Williams R, Lindridge M, Said A, Livermore D, Williams J . National survey of antibiotic resistance in Pseudomonas aeruginosa. J Antimicrob Chemother. 1984; 14(1):9-16. DOI: 10.1093/jac/14.1.9. View